Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 338 entries
Sorted by: Best Match Show Resources per page
Quantum back-action of an individual variable-strength measurement.

Science (New York, N.Y.)

Hatridge M, Shankar S, Mirrahimi M, Schackert F, Geerlings K, Brecht T, Sliwa KM, Abdo B, Frunzio L, Girvin SM, Schoelkopf RJ, Devoret MH.
PMID: 23307736
Science. 2013 Jan 11;339(6116):178-81. doi: 10.1126/science.1226897.

Measuring a quantum system can randomly perturb its state. The strength and nature of this back-action depend on the quantity that is measured. In a partial measurement performed by an ideal apparatus, quantum physics predicts that the system remains...

Cite
Hatridge M, Shankar S, Mirrahimi M, et al. Quantum back-action of an individual variable-strength measurement. Science. 2013;339(6116):178-81doi: 10.1126/science.1226897.
Hatridge, M., Shankar, S., Mirrahimi, M., Schackert, F., Geerlings, K., Brecht, T., Sliwa, K. M., Abdo, B., Frunzio, L., Girvin, S. M., Schoelkopf, R. J., & Devoret, M. H. (2013). Quantum back-action of an individual variable-strength measurement. Science (New York, N.Y.), 339(6116), 178-81. https://doi.org/10.1126/science.1226897
Hatridge, M, et al. "Quantum back-action of an individual variable-strength measurement." Science (New York, N.Y.) vol. 339,6116 (2013): 178-81. doi: https://doi.org/10.1126/science.1226897
Hatridge M, Shankar S, Mirrahimi M, Schackert F, Geerlings K, Brecht T, Sliwa KM, Abdo B, Frunzio L, Girvin SM, Schoelkopf RJ, Devoret MH. Quantum back-action of an individual variable-strength measurement. Science. 2013 Jan 11;339(6116):178-81. doi: 10.1126/science.1226897. PMID: 23307736.
Copy Download .nbib Format: NLM
Body Mass Index, Weight Gain during Pregnancy and Obstetric Outcomes.

Ghana medical journal

Addo VN.
PMID: 21327006
Ghana Med J. 2010 Jun;44(2):64-9. doi: 10.4314/gmj.v44i2.68886.

OBJECTIVES: To find out the effects of pregnancy weight gain in different body mass index (BMI) groups on maternal and neonatal outcomes in women delivering singletons at term.DESIGN: Retrospective analysis of clinical records of patients attending antenatal clinics and...

Cite
Addo VN. Body Mass Index, Weight Gain during Pregnancy and Obstetric Outcomes. Ghana Med J. 2010;44(2):64-9doi: 10.4314/gmj.v44i2.68886.
Addo, V. N. (2010). Body Mass Index, Weight Gain during Pregnancy and Obstetric Outcomes. Ghana medical journal, 44(2), 64-9. https://doi.org/10.4314/gmj.v44i2.68886
Addo, V N. "Body Mass Index, Weight Gain during Pregnancy and Obstetric Outcomes." Ghana medical journal vol. 44,2 (2010): 64-9. doi: https://doi.org/10.4314/gmj.v44i2.68886
Addo VN. Body Mass Index, Weight Gain during Pregnancy and Obstetric Outcomes. Ghana Med J. 2010 Jun;44(2):64-9. doi: 10.4314/gmj.v44i2.68886. PMID: 21327006; PMCID: PMC2994149.
Copy Download .nbib Format: NLM
Medication Noncompliance among Patients with Chronic Diseases Attending a Primary Health Facility in a Periurban District in Ghana.

International journal of chronic diseases

Addo B, Sencherey S, Babayara MNK.
PMID: 29977904
Int J Chronic Dis. 2018 Jun 07;2018:7187284. doi: 10.1155/2018/7187284. eCollection 2018.

BACKGROUND: Despite the growing interest in understanding the aetiology of chronic diseases, limited studies exist on medication noncompliance, especially, among periurban and rural dwellers in Ghana. In this study, we determined the prevalence of medication noncompliance and explored the...

Cite
Addo B, Sencherey S, Babayara MNK. Medication Noncompliance among Patients with Chronic Diseases Attending a Primary Health Facility in a Periurban District in Ghana. Int J Chronic Dis. 2018;2018:7187284doi: 10.1155/2018/7187284.
Addo, B., Sencherey, S., & Babayara, M. N. K. (2018). Medication Noncompliance among Patients with Chronic Diseases Attending a Primary Health Facility in a Periurban District in Ghana. International journal of chronic diseases, 20187187284. https://doi.org/10.1155/2018/7187284
Addo, Bright, et al. "Medication Noncompliance among Patients with Chronic Diseases Attending a Primary Health Facility in a Periurban District in Ghana." International journal of chronic diseases vol. 2018 (2018): 7187284. doi: https://doi.org/10.1155/2018/7187284
Addo B, Sencherey S, Babayara MNK. Medication Noncompliance among Patients with Chronic Diseases Attending a Primary Health Facility in a Periurban District in Ghana. Int J Chronic Dis. 2018 Jun 07;2018:7187284. doi: 10.1155/2018/7187284. eCollection 2018. PMID: 29977904; PMCID: PMC6011085.
Copy Download .nbib Format: NLM
Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring.

Hematology, transfusion and cell therapy

Seguro FS, Silva CMPDC, Moura CMB, Conchon M, Fogliatto L, Funke VAM, Abdo A, Macedo AVS, Santos MHHD, Saraiva JFK.
PMID: 32631809
Hematol Transfus Cell Ther. 2021 Apr-Jun;43(2):191-200. doi: 10.1016/j.htct.2020.04.009. Epub 2020 Jul 01.

This manuscript summarizes the results of the consensus meeting composed of hematologists and cardiologists to establish recommendations for the prevention and follow-up of cardiovascular (CV) risk in patients with chronic myeloid leukemia (CML) treated with BCR-ABL tyrosine kinase inhibitors...

Cite
Seguro FS, Silva CMPDC, Moura CMB, et al. Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring. Hematol Transfus Cell Ther. 2020;43(2):191-200doi: 10.1016/j.htct.2020.04.009.
Seguro, F. S., Silva, C. M. P. D. C., Moura, C. M. B., Conchon, M., Fogliatto, L., Funke, V. A. M., Abdo, A., Macedo, A. V. S., Santos, M. H. H. D., & Saraiva, J. F. K. (2021). Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring. Hematology, transfusion and cell therapy, 43(2), 191-200. https://doi.org/10.1016/j.htct.2020.04.009
Seguro, Fernanda Salles, et al. "Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring." Hematology, transfusion and cell therapy vol. 43,2 (2021): 191-200. doi: https://doi.org/10.1016/j.htct.2020.04.009
Seguro FS, Silva CMPDC, Moura CMB, Conchon M, Fogliatto L, Funke VAM, Abdo A, Macedo AVS, Santos MHHD, Saraiva JFK. Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring. Hematol Transfus Cell Ther. 2021 Apr-Jun;43(2):191-200. doi: 10.1016/j.htct.2020.04.009. Epub 2020 Jul 01. PMID: 32631809; PMCID: PMC8211634.
Copy Download .nbib Format: NLM
Corrigendum: Discovery of Novel and Clinically Relevant Markers in Formalin-Fixed Paraffin-Embedded Esophageal Cancer Specimen.

Frontiers in oncology

Abdo J, Wichman CS, Dietz NE, Ciborowski P, Fleegel J, Mittal SK, Agrawal DK.
PMID: 31032230
Front Oncol. 2019 Apr 12;9:273. doi: 10.3389/fonc.2019.00273. eCollection 2019.

[This corrects the article DOI: 10.3389/fonc.2018.00157.].

Cite
Abdo J, Wichman CS, Dietz NE, et al. Corrigendum: Discovery of Novel and Clinically Relevant Markers in Formalin-Fixed Paraffin-Embedded Esophageal Cancer Specimen. Front Oncol. 2019;9:273doi: 10.3389/fonc.2019.00273.
Abdo, J., Wichman, C. S., Dietz, N. E., Ciborowski, P., Fleegel, J., Mittal, S. K., & Agrawal, D. K. (2019). Corrigendum: Discovery of Novel and Clinically Relevant Markers in Formalin-Fixed Paraffin-Embedded Esophageal Cancer Specimen. Frontiers in oncology, 9273. https://doi.org/10.3389/fonc.2019.00273
Abdo, Joe, et al. "Corrigendum: Discovery of Novel and Clinically Relevant Markers in Formalin-Fixed Paraffin-Embedded Esophageal Cancer Specimen." Frontiers in oncology vol. 9 (2019): 273. doi: https://doi.org/10.3389/fonc.2019.00273
Abdo J, Wichman CS, Dietz NE, Ciborowski P, Fleegel J, Mittal SK, Agrawal DK. Corrigendum: Discovery of Novel and Clinically Relevant Markers in Formalin-Fixed Paraffin-Embedded Esophageal Cancer Specimen. Front Oncol. 2019 Apr 12;9:273. doi: 10.3389/fonc.2019.00273. eCollection 2019. PMID: 31032230; PMCID: PMC6474362.
Copy Download .nbib Format: NLM
A multicenter prospective phase II study of first-line modified FOLFIRINOX for unresectable advanced pancreatic cancer.

Oncotarget

Yoshida K, Iwashita T, Uemura S, Maruta A, Okuno M, Ando N, Iwata K, Kawaguchi J, Mukai T, Shimizu M.
PMID: 29340058
Oncotarget. 2017 Nov 30;8(67):111346-111355. doi: 10.18632/oncotarget.22795. eCollection 2017 Dec 19.

BACKGROUND: FOLFIRINOX (FX) has been reported as an effective treatment for unresectable advanced pancreatic cancer. However, FX is associated with a high incidence of adverse events (AEs). A previous phase II study in Japan showed high incidences of hematological...

Cite
Yoshida K, Iwashita T, Uemura S, et al. A multicenter prospective phase II study of first-line modified FOLFIRINOX for unresectable advanced pancreatic cancer. Oncotarget. 2017;8(67):111346-111355doi: 10.18632/oncotarget.22795.
Yoshida, K., Iwashita, T., Uemura, S., Maruta, A., Okuno, M., Ando, N., Iwata, K., Kawaguchi, J., Mukai, T., & Shimizu, M. (2017). A multicenter prospective phase II study of first-line modified FOLFIRINOX for unresectable advanced pancreatic cancer. Oncotarget, 8(67), 111346-111355. https://doi.org/10.18632/oncotarget.22795
Yoshida, Kensaku, et al. "A multicenter prospective phase II study of first-line modified FOLFIRINOX for unresectable advanced pancreatic cancer." Oncotarget vol. 8,67 (2017): 111346-111355. doi: https://doi.org/10.18632/oncotarget.22795
Yoshida K, Iwashita T, Uemura S, Maruta A, Okuno M, Ando N, Iwata K, Kawaguchi J, Mukai T, Shimizu M. A multicenter prospective phase II study of first-line modified FOLFIRINOX for unresectable advanced pancreatic cancer. Oncotarget. 2017 Nov 30;8(67):111346-111355. doi: 10.18632/oncotarget.22795. eCollection 2017 Dec 19. PMID: 29340058; PMCID: PMC5762326.
Copy Download .nbib Format: NLM
Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysis.

Oncology letters

Bonomi M, Ahmed T, Addo S, Kooshki M, Palmieri D, Levine BJ, Ruiz J, Grant S, Petty WJ, Triozzi PL.
PMID: 30655905
Oncol Lett. 2019 Jan;17(1):1349-1356. doi: 10.3892/ol.2018.9724. Epub 2018 Nov 19.

The combination of standard-dose chemotherapy and immunotherapy has been shown to be beneficial for patients with non-small cell lung cancer (NSCLC) with good performance status (PS). However, treatment options for patients with poor PS are limited. In the present...

Cite
Bonomi M, Ahmed T, Addo S, et al. Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysis. Oncol Lett. 2018;17(1):1349-1356doi: 10.3892/ol.2018.9724.
Bonomi, M., Ahmed, T., Addo, S., Kooshki, M., Palmieri, D., Levine, B. J., Ruiz, J., Grant, S., Petty, W. J., & Triozzi, P. L. (2019). Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysis. Oncology letters, 17(1), 1349-1356. https://doi.org/10.3892/ol.2018.9724
Bonomi, Marcelo, et al. "Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysis." Oncology letters vol. 17,1 (2019): 1349-1356. doi: https://doi.org/10.3892/ol.2018.9724
Bonomi M, Ahmed T, Addo S, Kooshki M, Palmieri D, Levine BJ, Ruiz J, Grant S, Petty WJ, Triozzi PL. Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysis. Oncol Lett. 2019 Jan;17(1):1349-1356. doi: 10.3892/ol.2018.9724. Epub 2018 Nov 19. PMID: 30655905; PMCID: PMC6312929.
Copy Download .nbib Format: NLM
Modulation of Diacylglycerol-Induced Melanogenesis in Human Melanoma and Primary Melanocytes: Role of Stress Chaperone Mortalin.

Evidence-based complementary and alternative medicine : eCAM

Wadhwa R, Li L, Singh R, Wang J, Gao R, Nigam N, Forestier S, Ando N, Kaul SC.
PMID: 31097976
Evid Based Complement Alternat Med. 2019 Apr 14;2019:9848969. doi: 10.1155/2019/9848969. eCollection 2019.

Skin color/pigmentation is regulated through melanogenesis process in specialized melanin-producing cells, melanocytes, involving multiple signaling pathways. It is highly influenced by intrinsic and extrinsic factors such as oxidative, ultraviolet radiations and other environmental stress conditions. Besides determining the color,...

Cite
Wadhwa R, Li L, Singh R, et al. Modulation of Diacylglycerol-Induced Melanogenesis in Human Melanoma and Primary Melanocytes: Role of Stress Chaperone Mortalin. Evid Based Complement Alternat Med. 2019;2019:9848969doi: 10.1155/2019/9848969.
Wadhwa, R., Li, L., Singh, R., Wang, J., Gao, R., Nigam, N., Forestier, S., Ando, N., & Kaul, S. C. (2019). Modulation of Diacylglycerol-Induced Melanogenesis in Human Melanoma and Primary Melanocytes: Role of Stress Chaperone Mortalin. Evidence-based complementary and alternative medicine : eCAM, 20199848969. https://doi.org/10.1155/2019/9848969
Wadhwa, Renu, et al. "Modulation of Diacylglycerol-Induced Melanogenesis in Human Melanoma and Primary Melanocytes: Role of Stress Chaperone Mortalin." Evidence-based complementary and alternative medicine : eCAM vol. 2019 (2019): 9848969. doi: https://doi.org/10.1155/2019/9848969
Wadhwa R, Li L, Singh R, Wang J, Gao R, Nigam N, Forestier S, Ando N, Kaul SC. Modulation of Diacylglycerol-Induced Melanogenesis in Human Melanoma and Primary Melanocytes: Role of Stress Chaperone Mortalin. Evid Based Complement Alternat Med. 2019 Apr 14;2019:9848969. doi: 10.1155/2019/9848969. eCollection 2019. PMID: 31097976; PMCID: PMC6487102.
Copy Download .nbib Format: NLM
Early separation of omphalopagus conjoined twins: a case report from Syria.

Journal of surgical case reports

Omran A, Nassif M, Salhab N, Abdo A, Almahmod Alkhalil MA, Taishori N, Dayoub A.
PMID: 32015822
J Surg Case Rep. 2020 Jan 30;2020(1):rjz374. doi: 10.1093/jscr/rjz374. eCollection 2020 Jan.

Omphalopagus twins are one of many forms of conjoined twins sharing part of the gastrointestinal system and abdominal wall. This type of twins has the best chance of survival if successfully separated. Surgical approaches in these cases are generally...

Cite
Omran A, Nassif M, Salhab N, et al. Early separation of omphalopagus conjoined twins: a case report from Syria. J Surg Case Rep. 2020;2020(1):rjz374doi: 10.1093/jscr/rjz374.
Omran, A., Nassif, M., Salhab, N., Abdo, A., Almahmod Alkhalil, M. A., Taishori, N., & Dayoub, A. (2020). Early separation of omphalopagus conjoined twins: a case report from Syria. Journal of surgical case reports, 2020(1), rjz374. https://doi.org/10.1093/jscr/rjz374
Omran, Ammar, et al. "Early separation of omphalopagus conjoined twins: a case report from Syria." Journal of surgical case reports vol. 2020,1 (2020): rjz374. doi: https://doi.org/10.1093/jscr/rjz374
Omran A, Nassif M, Salhab N, Abdo A, Almahmod Alkhalil MA, Taishori N, Dayoub A. Early separation of omphalopagus conjoined twins: a case report from Syria. J Surg Case Rep. 2020 Jan 30;2020(1):rjz374. doi: 10.1093/jscr/rjz374. eCollection 2020 Jan. PMID: 32015822; PMCID: PMC6990099.
Copy Download .nbib Format: NLM
Novel inhibitors against wild-type and mutated HCV NS3 serine protease: an in silico study.

Virusdisease

Ezat AA, Elfiky AA, Elshemey WM, Saleh NA.
PMID: 31179358
Virusdisease. 2019 Jun;30(2):207-213. doi: 10.1007/s13337-019-00516-7. Epub 2019 Mar 21.

In 2011, the FDA approved boceprevir as a hepatitis C virus (HCV) NS3 serine protease inhibitor. The sustained virological response rate for treatment with this approved compound is considerably low. Patients have not responded as much as expected to...

Cite
Ezat AA, Elfiky AA, Elshemey WM, et al. Novel inhibitors against wild-type and mutated HCV NS3 serine protease: an in silico study. Virusdisease. 2019;30(2):207-213doi: 10.1007/s13337-019-00516-7.
Ezat, A. A., Elfiky, A. A., Elshemey, W. M., & Saleh, N. A. (2019). Novel inhibitors against wild-type and mutated HCV NS3 serine protease: an in silico study. Virusdisease, 30(2), 207-213. https://doi.org/10.1007/s13337-019-00516-7
Ezat, Ahmed A, et al. "Novel inhibitors against wild-type and mutated HCV NS3 serine protease: an in silico study." Virusdisease vol. 30,2 (2019): 207-213. doi: https://doi.org/10.1007/s13337-019-00516-7
Ezat AA, Elfiky AA, Elshemey WM, Saleh NA. Novel inhibitors against wild-type and mutated HCV NS3 serine protease: an in silico study. Virusdisease. 2019 Jun;30(2):207-213. doi: 10.1007/s13337-019-00516-7. Epub 2019 Mar 21. PMID: 31179358; PMCID: PMC6531565.
Copy Download .nbib Format: NLM
The probability of response after each subcutaneous injection of esketamine in treatment-resistant depression.

Revista de psiquiatria y salud mental

Fava VAR, Sarin LM, Lucchese AC, Del Sant L, Magalhães E, Delfino RS, Tuena MA, Nakahira C, Jackowski AP, Abdo G, Surjan J, Steiglich M, Barbosa MG, Porto JAD, Lacerda ALT, Cogo-Moreira H.
PMID: 34861929
Rev Psiquiatr Salud Ment (Engl Ed). 2021 Oct-Dec;14(4):212-217. doi: 10.1016/j.rpsmen.2021.11.003.

INTRODUCTION: The administration of multiple esketamine doses has shown efficacy for unipolar and bipolar treatment-resistant depression (TRD). Nevertheless, the probability of responding or not after each dose in the real-world remains unknown. This study aimed to estimate it throughout...

Cite
Fava VAR, Sarin LM, Lucchese AC, et al. The probability of response after each subcutaneous injection of esketamine in treatment-resistant depression. Rev Psiquiatr Salud Ment (Engl Ed). 2021;14(4):212-217doi: 10.1016/j.rpsmen.2021.11.003.
Fava, V. A. R., Sarin, L. M., Lucchese, A. C., Del Sant, L., Magalhães, E., Delfino, R. S., Tuena, M. A., Nakahira, C., Jackowski, A. P., Abdo, G., Surjan, J., Steiglich, M., Barbosa, M. G., Porto, J. A. D., Lacerda, A. L. T., & Cogo-Moreira, H. (2021). The probability of response after each subcutaneous injection of esketamine in treatment-resistant depression. Revista de psiquiatria y salud mental, 14(4), 212-217. https://doi.org/10.1016/j.rpsmen.2021.11.003
Fava, Victor Augusto Rodovalho, et al. "The probability of response after each subcutaneous injection of esketamine in treatment-resistant depression." Revista de psiquiatria y salud mental vol. 14,4 (2021): 212-217. doi: https://doi.org/10.1016/j.rpsmen.2021.11.003
Fava VAR, Sarin LM, Lucchese AC, Del Sant L, Magalhães E, Delfino RS, Tuena MA, Nakahira C, Jackowski AP, Abdo G, Surjan J, Steiglich M, Barbosa MG, Porto JAD, Lacerda ALT, Cogo-Moreira H. The probability of response after each subcutaneous injection of esketamine in treatment-resistant depression. Rev Psiquiatr Salud Ment (Engl Ed). 2021 Oct-Dec;14(4):212-217. doi: 10.1016/j.rpsmen.2021.11.003. PMID: 34861929.
Copy Download .nbib Format: NLM
Benefits of Tocilizumab in patients with a severe form of SARS-CoV-2 infection: Experience of the intensive care unit of the Mohammed VI university hospital, Oujda.

Annals of medicine and surgery (2012)

El Rhalete A, Rhazi I, Bensaid A, Diass S, Kaouini A, Ounci E, Abdi M, Maarad M, Babouh C, Alami Z, Abda N, Bkiyer H, Housni B.
PMID: 34221397
Ann Med Surg (Lond). 2021 Jul;67:102514. doi: 10.1016/j.amsu.2021.102514. Epub 2021 Jun 25.

BACKGROUND: COVID-19 is a new disease that appeared in December 2019. Millions of people have been infected and died from this infection. Until today, the pathophysiology and treatment of this infection remain unknown, but a lot of studies are...

Cite
El Rhalete A, Rhazi I, Bensaid A, et al. Benefits of Tocilizumab in patients with a severe form of SARS-CoV-2 infection: Experience of the intensive care unit of the Mohammed VI university hospital, Oujda. Ann Med Surg (Lond). 2021;67:102514doi: 10.1016/j.amsu.2021.102514.
El Rhalete, A., Rhazi, I., Bensaid, A., Diass, S., Kaouini, A., Ounci, E., Abdi, M., Maarad, M., Babouh, C., Alami, Z., Abda, N., Bkiyer, H., & Housni, B. (2021). Benefits of Tocilizumab in patients with a severe form of SARS-CoV-2 infection: Experience of the intensive care unit of the Mohammed VI university hospital, Oujda. Annals of medicine and surgery (2012), 67102514. https://doi.org/10.1016/j.amsu.2021.102514
El Rhalete, Abdelilah, et al. "Benefits of Tocilizumab in patients with a severe form of SARS-CoV-2 infection: Experience of the intensive care unit of the Mohammed VI university hospital, Oujda." Annals of medicine and surgery (2012) vol. 67 (2021): 102514. doi: https://doi.org/10.1016/j.amsu.2021.102514
El Rhalete A, Rhazi I, Bensaid A, Diass S, Kaouini A, Ounci E, Abdi M, Maarad M, Babouh C, Alami Z, Abda N, Bkiyer H, Housni B. Benefits of Tocilizumab in patients with a severe form of SARS-CoV-2 infection: Experience of the intensive care unit of the Mohammed VI university hospital, Oujda. Ann Med Surg (Lond). 2021 Jul;67:102514. doi: 10.1016/j.amsu.2021.102514. Epub 2021 Jun 25. PMID: 34221397; PMCID: PMC8233060.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 338 entries